Study of niraparib with radiotherapy for treatment of metastatic invasive carcinoma of the cervix (NIVIX) (H-42584)

This study is a phase I/II study of women diagnosed with distantly metastatic (Stage IV) disease to determine the maximum tolerated dose and to evaluate the safety, tolerability and preliminary efficacy of niraparib, an orally available small molecule PARP inhibitor when administered concurrently with definitive regional radiotherapy for treatment of cervical cancer.